Transcripta Bio raised $24 million since its Series A to advance IND-enabling work across its pipeline and prepare for clinical execution. The company said the financing supports programs in autism spectrum disorder and facioscapulohumeral muscular dystrophy, with additional efforts in myotonic dystrophy and Huntington’s disease. The raise signals continued investor support for RNA- and neuro-adjacent platforms seeking to convert preclinical biology into IND dossiers. For the biotech community, it adds to the ongoing funding flow into early-stage development across neurodegeneration and neurodevelopmental indications.